Parakeet Health is a healthcare-native voice AI that automates the front office — scheduling, referral intake, recalls, cancellations, and FAQs — across voice, SMS, fax, and email, and it has turned that product into a repeatable enterprise sales motion faster than any peer we track. The wedge is verticalization: rather than sell horizontally, Parakeet ran a dermatology-first playbook and now serves three of the top five U.S. dermatology groups, ~430 clinics and ~1,050 providers (Internal), replacing legacy incumbents like Freesia with measurably better backfill and conversion rates. Implementation that once took 10 months has been compressed to ~4 weeks, which is what makes the enterprise motion repeatable.
The company scaled committed ARR from $300K to $3.1M+ in nine months, closed marquee logos (Schweiger Dermatology, Talkspace, Essen Health), and is now moving to solution and per-patient-per-month pricing (Internal). Canvas is leading the $10M priced Series A at a $50M post ($40M pre) with a $7M check; Runa Capital — a healthcare investor with a DrChrono exit — is co-investing and taking an observer seat (Internal / Web). StoryHouse committed $149,997 via Fund I as a follow-on: 53,304 new A-1 shares at $2.8140, plus its original $300K SAFE converting into 252,312 A-3 shares at $1.1890. This is a conviction follow-on into an accelerating portfolio company, priced at a full step-up.
The AI voice-agents-in-healthcare segment is small today (~$650M in 2026) but is the fastest-growing corner of healthcare AI, compounding at ~37–38% and reaching an estimated $3.2B by 2030 (Web). It sits inside the broader ~$24.7B AI patient-engagement market growing ~21% (Web). Why now: provider staffing shortages, LLM-native call automation crossing the quality bar, and payers/practices rewarding measurable access gains make this a genuine "cost center becomes revenue engine" moment — exactly the wedge Parakeet is selling.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Parakeet Health | Healthcare-native voice AI; verticalized (derm-first); pay-for-performance pricing | Series A, $10M @ $50M post Internal | — |
| Assort Health | Specialty-specific AI for patient phone calls | Series B, $50M @ $750M Web | Assort is far better capitalized; Parakeet counters on capital efficiency and enterprise-derm depth |
| Hello Patient | End-to-end patient conversations across voice, text, chat | Series A, $22.5M Web | Comparable stage; Parakeet leads on marquee enterprise logos and implementation speed |
| Hyro | Conversational AI / responsible-AI assistants for health systems | Growth-stage Web | Parakeet is more autonomous and outcome-priced vs. assistant/deflection framing |
| Legacy (e.g. Freesia) | Incumbent patient-access / rescheduling software | Public / incumbent Internal | Parakeet displaced Freesia at Schweiger on superior backfill/conversion rates |
Moat: Vertical depth and switching costs — deep EHR/PM integrations plus a proof-carrying, derm-specific dataset that compounds outcome accuracy and makes Parakeet hard to rip out once embedded across a group's clinics.
Likely acquirers are EHR/practice-management platforms and revenue-cycle/patient-access consolidators (e.g. Modernizing Medicine in derm, Waystar/IKS Health-type RCM buyers), plus larger voice-AI peers rolling up the category (Web). Recent comps are supportive: Assort Health reached a $750M valuation on its Series B, and healthcare AI patient-access M&A is active (IKS Health / ThinkDTM acquihire, March 2026) (Web). Against a $50M entry post, a mid-hundreds-of-millions strategic outcome returns Fund I's follow-on roughly 8–15x; the SAFE conversion at $1.1890 vs. the $2.8140 A-1 price meaningfully improves blended cost basis.
Jung called to flag that Runa Capital (Michael Fatant, observer seat) is co-investing alongside Canvas' $7M, and asked SH to trim its check to accommodate.
Email from Jung: Parakeet signed a term sheet with Canvas for a $10M (max) priced Series A at $50M post-money, larger than planned.
Catch-up with Jung on the pending raise, current metrics, and his read on the healthcare voice-AI market.